The system, an intra-operative tissue assessment tool for early-stage breast cancer surgery, is intended to enable real-time detection of cancer at or near the surface of excised tissue specimens during breast cancer surgery. MarginProbe uses electromagnetic “signatures” to identify healthy and cancerous tissue during lumpectomy.
“The MarginProbe system was developed to address one of the longest standing unmet medical needs in the breast cancer surgical community,” said Daniel Levangie, CEO of Dune Medical Devices, in the release. “We have received resounding support from clinicians, advocacy organizations and patients alike, who have recognized the value of MarginProbe and intra-operative, real-time detection of cancer on the margin to potentially improve patient outcomes.”
Dune Medical Devices has offices in the United States, Israel and Switzerland.
Related Articles on FDA Clearances:
Medical Modeling Receives FDA Clearance for Virtual Surgical Planning System
EndoChoice Receives FDA Clearance for Water Bottle Cap Irrigation System
Avinger Receives FDA Clearance for Smaller, Longer Optical Coherence Tomography Catheter
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
